Another meta-analysis indicated that the incidence of hypertension among patients receiving bevacizumab (an anti-VEGF antibody) was 8% (95% CI, 6-10%), and that the danger for the onset of hypertension in individuals treated with bevacizumab increased significantly (RR, 5.38; 95% CI, 3.63-7.97) [91]. Here, VEGFA is linked to hypertensive disorder.